Applied Materials, Intel collaborate on AI chipmaking technology development
Bitget2026/10/06 13:02Applied Materials entered a collaboration with Intel to speed development of chipmaking technology for AI-driven computing. Work will span next-generation transistors, interconnect scaling, and advanced packaging aimed at faster time-to-market. R&D will be coordinated between Applied’s EPIC Center in Silicon Valley and Intel’s R&D campus in Hillsboro, Oregon. Partnership includes advanced packaging for Foveros-based 3D stacking to boost interconnect density, power delivery, and thermal performance. EPIC Center is scheduled to be operationally ready this year, targeting faster transfer from research to high-volume manufacturing in the US. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Applied Materials Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610060900PRIMZONEFULLFEED9840132) on October 06, 2026, and is solely responsible for the information contained therein.
- Applied Materials entered a collaboration with Intel to speed development of chipmaking technology for AI-driven computing.
- Work will span next-generation transistors, interconnect scaling, and advanced packaging aimed at faster time-to-market.
- R&D will be coordinated between Applied’s EPIC Center in Silicon Valley and Intel’s R&D campus in Hillsboro, Oregon.
- Partnership includes advanced packaging for Foveros-based 3D stacking to boost interconnect density, power delivery, and thermal performance.
- EPIC Center is scheduled to be operationally ready this year, targeting faster transfer from research to high-volume manufacturing in the US.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley raises CME Group price target to $337
Chip design software leader Synopsys seeks collaboration with Chinese large model laboratories
Former BioNTech executive leads Bambusa Therapeutics (BBTX.US) in sprint to Nasdaq, "boosting" eczema drug trials
Bambusa Therapeutics Inc. has filed for an initial public offering, planning to raise funds for clinical trials of treatments for eczema and other inflammatory diseases.
Crypto prices
More
